 Preventive Process Stabilization by Integrated Process DevelopmentThomas Friedli () and
Reto Ziegler ()
Chapter Chapter 17 in Leading Pharmaceutical Operational Excellence, 2013, pp 263-283 from Springer Abstract: Abstract Compared to other industries, pharmaceutical companies still work as an assembly of functions rather than as a seamlessly integrated operation. Co-existing functions and departments do not, or only to a small extent, collaborate. This especially applies to pharma’s central value stream of research – development – production. Although there are often clear interfaces between these major functions, they usually are rather narrow. Since projects from research through development to commercial manufacturing have a long lifespan, they are rarely overseen from beginning to end, but instead are independently assessed during these three distinct phases. This results in an overall lack of dedication to the success of a project; the goal is mainly to get a project successfully through one’s own phase, without much consideration of subsequent requirements and specifics. Keywords: Success Factor; High Performer; Integrate Development; Launch Site; Commercial Manufacturing (search for similar items in EconPapers) There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it. Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-642-35161-7_17 Ordering information: This item can be ordered from DOI: 10.1007/978-3-642-35161-7_17 Access Statistics for this chapter More chapters in Springer Books from Springer |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.